Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in
intravascular robotics, today announced it will showcase its
Magellan™ Robotic System at the 35th Annual Charing Cross
International Symposium from April 6-9 in London. The Company will
be exhibiting the Magellan Robotic System at Booth 628.
In addition, Professor Nick Cheshire, MD of St. Mary's Hospital,
part of the Imperial College Healthcare NHS Trust in London, and
Barry Katzen, MD, founder and Medical Director of the Baptist
Cardiac & Vascular Institute (Baptist Hospital of Miami), will
participate in a panel discussion titled, "Great Debate: Influence
of Robotics and Simulators," during the "Carotid Challenges"
session at 10:00 am on Tuesday, April 9.
Hansen Medical will also be co-sponsoring a symposium with
Philips Healthcare from 12:30 pm-3:30 pm on Monday, April 8 in the
Green Learning Center, titled "Advanced Imaging in the Hybrid
Operating Room." This symposium will feature Dr. Katzen who will
discuss his clinical experiences with the Magellan System in a
variety of interventional procedures.
Lastly, on Sunday, April 7 at 4:45 pm Professor Jean-Pierre
Becquemin, MD of Creteil, France will present on his experiences
with the Magellan System in a presentation titled, "Early
Experiences with Intravascular Robotics."
"We are pleased that our Magellan Robotic System will be
highlighted at Charing Cross, Europe's longest running and leading
vascular symposium," said Bruce Barclay, President and CEO of
Hansen Medical. "The presentations featuring our technology will
provide additional opportunities for clinicians to better
understand the significant clinical and economic benefits, and real
world medical utility, provided by the Magellan System. We are also
excited to be co-hosting a symposium with our partner Philips for
the second consecutive year. Since commencing the initial U.S.
launch of the Magellan System last June, we have generated a large
and growing pipeline of clinical interest in our robotic
technology, and we look forward to further building on this
momentum at Charing Cross."
"At St. Mary's, we have performed a breadth of complex
endovascular procedures with the Magellan Robotic System in the
past year," said Professor Cheshire. "Charing Cross, being the
premier European endovascular event, affords us the opportunity to
discuss the clinical benefits we're seeing through the
implementation of intravascular robotics."
About the Magellan™ Robotic System
Hansen Medical's Magellan Robotic System is based upon the
flexible robotic technology incorporated in the Sensei-X® Robotic
Catheter System currently sold in the U.S. and Europe, which has
been used in excess of 10,000 patients, but includes a number of
key enhancements. In particular, the Magellan Robotic System:
- Provides solid catheter stability for placement of therapeutic
devices.
- Is designed to enable predictable procedure times and increased
case throughput.
- Allows for independent, individual robotic control of the
distal tips of both the outer sheath and the inner leader catheter,
as well as robotic manipulation of standard guidewires.
- Is designed to allow for sufficient extension inside the body
to access hard to reach peripheral anatomy.
- Preserves the open architecture featured in the Sensei System
to allow for the subsequent use of many 6F therapeutic devices on
the market today.
- Is designed to potentially reduce physician radiation exposure
and fatigue by employing a remote physician workstation.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is the
global leader in intravascular robotics, developing products and
technology designed to enable the accurate positioning,
manipulation and control of catheters and catheter-based
technologies. The Company's Magellan™ Robotic System, NorthStar™
Robotic Catheter and related accessories, which are intended to
facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices, have undergone both CE marking and 510(k)
clearance and are commercially available in the European Union, and
the U.S. In the European Union, the Company's Sensei® X Robotic
Catheter System and Artisan Control Catheter are cleared for use
during electrophysiology (EP) procedures, such as guiding catheters
in the treatment of atrial fibrillation (AF), and the Lynx® Robotic
Ablation Catheter is cleared for the treatment of AF. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the U.S. the
Company's Sensei X Robotic Catheter System and Artisan Control
Catheter were cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the United States, the Sensei System is not approved
for use in guiding ablation procedures; this use remains
experimental. The U.S. product labeling therefore provides that the
safety and effectiveness of the Sensei X System and Artisan Control
Catheter for use with cardiac ablation catheters in the treatment
of cardiac arrhythmias, including AF, have not been established.
Additional information can be found at www.hansenmedical.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding, among other things, statements relating to goals, plans,
objectives, milestones and future events. All statements, other
than statements of historical fact, are statements that could be
deemed forward-looking statements, including statements containing
the words "plan," "expects," "potential," "believes," "goal,"
"estimate," "anticipates," and similar words. These statements are
based on the current estimates and assumptions of our management as
of the date of this press release and are subject to risks,
uncertainties, changes in circumstances and other factors that may
cause actual results to differ materially from the information
expressed or implied by forward-looking statements made in this
press release. Examples of such statements include statements about
the potential benefits of our Magellan Robotic System for
hospitals, patients and physicians, expectations of shipments and
installations of our robotic systems, catheter sales, and
procedures, expectations of gross margins and operating expenses
for 2013, the sufficiency of the company's cash resources for
supporting the Company's operations, expected efficiencies from
cost saving initiatives, and the anticipated timing of commercially
launching a 6F vascular catheter. Important factors that could
cause actual results to differ materially from those indicated by
such forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; the commercial
viability of our products in the vascular markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of economic conditions on capital spending by our potential
customers; the uncertain timelines for the sales cycle for newly
introduced products; the rate of adoption of our systems and the
rate of use of our catheters; the scope and validity of
intellectual property rights applicable to our products;
competition from other companies; our ability to recruit and retain
key personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully
described in the "Risk Factors" section of our Annual Report on
Form 10-K for the year ended December 31, 2012 filed with the SEC
on March 18, 2013 and the risks discussed in our other reports
filed with the SEC. Given these uncertainties, you should not place
undue reliance on the forward-looking statements in this press
release. We undertake no obligation to revise or update information
herein to reflect events or circumstances in the future, even if
new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial
Officer Hansen Medical, Inc. 650.404.5800 FTI Consulting,
Inc. Brian Ritchie 212.850.5683 Email Contact John Capodanno
212.850.5705 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024